The Incidence of Fractures in Prader-Willi Syndrome across the Age Spectrum

Research Article

J Pediatri Endocrinol. 2016; 1(2): 1008.

The Incidence of Fractures in Prader-Willi Syndrome across the Age Spectrum

Gross-Tsur V1,2,3, Altarescu G3,4, Eldar-Geva T1,3,5, Pollak Y6 and Hirsch HJ1*

¹Department of Neuropediatrics, Shaare Zedek Medical Center, Jerusalem, Israel

²Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel

³Department of Medicine, The Hebrew University, Jerusalem, Israel

4Department of Genetics, Shaare Zedek Medical Center, Jerusalem, Israel

5Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel

6Department of Education, The Hebrew University, Jerusalem, Israel

*Corresponding author: Hirsch HJ, Department of Neuropediatrics, Shaare Zedek Medical Center, Jerusalem, Israel

Received: July 25, 2016; Accepted: October 12, 2016; Published: October 14, 2016

Abstract

Background: Osteoporosis is a common feature of Prader-Willi Syndrome (PWS), but the true incidence of fractures from infancy through adulthood in this population has not been previously studied.

Objective: Characterize the incidence of fractures across the age spectrum in the Israeli PWS cohort.

Methods: Clinic charts of all 160 individuals with genetically confirmed PWS known to the national PWS multidisciplinary clinic were reviewed. Parents or caregivers were contacted by telephone to confirm and update data regarding the incidence of fractures. Two families were lost to follow-up. The study group consisted of 158 individuals (81 M/77 F) from age 4 months to 52.8 years.

Results: One or more fractures were reported in 35 (22.2%) individuals: 17 M/18 F, ages 4.7-52.8 years (23.2±10.3). For the remaining 123 (76.9%) individuals there was no history of fractures: 64 M/59 F ages 0.4-41.3 years (11.7±10.1). The youngest age at fracture onset was 1.5 years and the oldest was 40 years. Fractures were reported in 5.0%, 25.7% and 50.0% of individuals ages 0.4-11.9, 12-20 and >20 years, respectively. Twenty-four of the 35 individuals with fractures had one fracture; the other eleven had two to three fractures. For adults, BMI was 29.9±5.8 kg/m² in the fracture group compared with 35.2±5.8 kg/m² in those with no fractures (NS).

Conclusion: Fractures are frequent in individuals with PWS. The incidence correlates with age and is greater in individuals with UPD. Sex and BMI were not risk factors for fracture occurrence. Exercise programs as well as medications may help prevent osteoporosis and should be tailored to each patient’s hormonal and anthropometric profile.

Keywords: Prader-Willi syndrome; Fractures; Bone mineral density; Osteoporosis

Abbreviations

BMI: Body Mass Index; PWS: Prader-Willi Syndrome; GH: Growth Hormone; DEL: Deletion; UPD: Uniparental Disomy; IC: Imprinting Center Defect; MOS: Mosaicism; UN: Unknown

Introduction

Prader-Willi Syndrome (PWS) is a neurogenetic disorder characterized by variable expression of physical, cognitive and behavioral impairments. Hyperphagia and morbid obesity, hypotonia, hypogonadism and growth hormone deficiency are among the major features of this syndrome. The genetic basis for PWS is the absence of paternally expressed imprinted genes at 15q11.2-q13 due to deletion of this region on the paternally-inherited chromosome (65- 75% of individuals), maternal uniparental disomy (20-30%), or an imprinting center defect (1-3%) [1]. Because of the low bone mineral density (BMD), the risk of fractures is increased, particularly in long bones [2]. Fractures can cause significant pain, disability, reduced quality of life and may result in premature death [3].

The incidence of fractures in PWS was estimated to be 24- 44% according to two reports based on relatively small series [2,4]. Among PWS adults, the incidence of fractures was reported to be 44% [5]. There are, however, no data, regarding fracture incidence in a large PWS cohort across the entire age spectrum. In this report, we describe the occurrence of fractures in a large, nationwide cohort of PWS individuals from infancy to adulthood.

Patient Population and Methods

This study was approved by the institutional review board of the Shaare Zedek Medical Center, Jerusalem, Israel. Written informed consent was obtained from participants, parents and/or legal guardians.

Of 160 patients with genetically documented PWS followed in the Israel national multidisciplinary clinic at the Shaare Zedek Medical Center in Jerusalem, 158 (81 males, 77 females) participated in the study. Ages ranged from 4 months to 52.8 years. We divided the patients into three age groups: 79 children (4 months-11.9 years), 35 adolescents (12.0 to 19.9 years) and 44 adults (20.0-52.8 years). Characteristics of the study population including genetic subtypes are shown in (Table 1). 35 of the 81 male participants and 36 of the 77 female participants were or had been treated with recombinant human growth hormone. Four of the 25 male participants and 2 of the 19 female participants were or had been treated with sex hormones (testosterone or estrogen preparations). Supplemental vitamin D at a dose range of 600 to 1,000 I.U. daily was prescribed to each patient, but compliance was highly variable.

Citation: Gross-Tsur V, Altarescu G, Eldar-Geva T, Pollak Y and Hirsch HJ. The Incidence of Fractures in Prader- Willi Syndrome across the Age Spectrum. J Pediatri Endocrinol. 2016; 1(2): 1008.